Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 3, 2013, Pages 669-671

  Chande, Nilesh ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Crohn's disease; Deep vein thrombosis; Heparin; Ulcerative colitis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; PARNAPARIN; PLACEBO; REVIPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; COCHRANE LIBRARY; COLON RESECTION; CROHN DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; LUNG EMBOLISM; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REMISSION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84876356372     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31827e7a0f     Document Type: Review

References (22)

1. Chande N, McDonald JW, MacDonald JK, et al. Unfractionated or lowmolecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(10):CD006774.
2. Zitomersky NL, Verhave M, Trenor CC. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention. Inflamm Bowel Dis. 2011;17:458-470.
3. Di Fabio F, Lykoudis P, Gordon PH. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. Semin Thromb Hemost. 2011;37:220-225.
4. Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937-943.
5. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011; 106:713-718.
6. Nguyen GC, Sam MD. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272-2280.
7. Merrill A, Millham F. Increased risk of postoperative deep vein thrombosis and pulmonary embolism in patients with inflammatory bowel disease: a study of National Surgical Quality Improvement Program patients. Arch Surg. 2012;147:120-124.
8. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
9. Leizorovica A, Cohen AT, Turpie AGG, et al. Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879.
10. Zhernakova TV, Kashmenskaia NA, Mal'tseva IV, et al. [Hemostasis and heparin therapy in nonspecific ulcerative colitis]. Sov Med. 1984; (2):110-113.
11. Zavgorodnii LG, Mustiats AP. Use of anticoagulants in the combined treatment of nonspecific ulcerative colitis. Klin Med (Mosk). 1982;60: 74-80.
12. Chande N, McDonald JW, MacDonald JK. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2008;(2):CD006774.
13. Panes J, Esteve M, Cabre E, et al. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology. 2000;119:903-908.
14. Bloom S, Kiilerich S, Lassen M, et al. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:871-878.
15. Celasco G, Papa A, Jones R, et al. Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2010;31:375-386.
16. de Bievre MA, Vrij AA, Schoon EJ, et al. Randomized, placebo-controlled trial of low molecular weight heparin in ulcerative colitis. Inflamm Bowel Dis. 2007;13:753-758.
17. Zezos P, Papaioannou G, Nikolaidis N, et al. Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Aliment Pharmacol Ther. 2006;23:1443-1453.
18. Geerts WH, Berqqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
19. Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523.
20. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571-607.
21. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis. 2008;2:24-62.
22. Van Assche G, Dignass A, Reinisch, et al. The second European evidence- based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.